Project details

The COBALT trial aims to find out if adding Memantine to acetylcholinesterase inhibitors improves overall health and functioning for people with DLB or PDD.

 

About the study

The COBALT Trial aims to find out if adding Memantine to acetylcholinesterase inhibitors improves overall health and functioning for people with DLB or PDD and to determine the clinical and cost effectiveness of up to 12 months therapy, with up to 20mg daily oral memantine in addition to Acetylcholinesterase inhibitor therapy in people with dementia with Lewy bodies (COBALT-DLB) and Parkinson’s Disease Dementia (COBALT-PDD). Participants will be randomised into two trial medication groups: either a placebo group or the treatment group.

 

 

Who can take part?

• Individuals who have a diagnosis of DLB or PDD
• Aged 55years +
• Receiving a stable dose of memory medication for 12weeks
• Stable on any antiparkinsonian treatment, antidepressants, anxiolytics or antipsychotics for 4 weeks
• Have a caregiver/ informant 

 

What does this study involve?

• You will have planned visits and phone calls with the local trial team who will ask you questions about your symptoms, behaviours and how you feel while you are taking part in the trial.
• You will have a ‘trial partner’, who will be asked also to answer questions about you and about themselves
• You will be asked to complete a participant diary to help track your medication use and if you feel unwell. Your trial partner can help you complete this.

 

How can I take part?

Contact researchinfo@nsft.nhs.uk

 

Click here to find out more about research opportunities